Minneslate Logo

SF2806 (Legislative Session 94 (2025-2026))

Prescription monitoring program provisions modifications

Related bill: HF2624

AI Generated Summary

Purpose of the Bill

The bill aims to amend certain provisions in Minnesota's Prescription Monitoring Program (PMP) to better monitor and manage the distribution of controlled substances in the state.

Main Provisions

  • Definition Updates: Expands the definition of controlled reportable substances to include substances like butalbital, gabapentin, and FDA-approved opioid overdose reversal agents.
  • Prescription Electronic Reporting System: Mandates an electronic system for tracking controlled substances, and authorizes the board to contract vendors for technical support.
  • Data Reporting and Submission: Requires dispensers to submit detailed information about prescriptions to a central database, including patient and prescriber details, while outlining exemptions.
  • Data Use and Access: Specifies permissible users who can access the prescription data, including prescribers, pharmacists, law enforcement, and certain state personnel, under strict conditions.
  • Patient Access: Allows patients to request access to their own prescription data records to see who has accessed them, requiring a formal submission to the board.
  • Data Retention and Destruction: Sets guidelines for how long data can be retained and requires old data to be destroyed after specified timeframes.

Significant Changes to Existing Law

  • Enhanced Data Privacy: Provides clear definitions around the privacy and usage of individual prescription data to prevent misuse and unauthorized access.
  • Increased Oversight: Introduces audits and security measures to ensure compliance with the new provisions.
  • Expanded Access: Clarifies which state departments and program personnel can directly access data for monitoring compliance and patient management.
  • Patient Rights: Expands patient rights to access their prescription records to enhance transparency.

Relevant Terms

  • Prescription Monitoring Program (PMP)
  • Controlled substances
  • Prescription electronic reporting system
  • Dispensing and prescriber data
  • Data privacy and security
  • Gabapentin, butalbital
  • Opioid overdose reversal agents
  • Patient data access and privacy
  • Data retention and destruction
  • Minnesota State Board of Pharmacy

Bill text versions

Actions

DateChamberWhereTypeNameCommittee Name
March 19, 2025SenateFloorActionIntroduction and first reading
March 19, 2025SenateFloorActionReferred toHealth and Human Services

Citations

 
[
  {
    "analysis": {
      "added": [
        "Clarifies the access and use protocol for data by specific healthcare professionals and governmental bodies.",
        "Mandates quarterly audits for compliance with permissible use standards."
      ],
      "removed": [
        "Omitted the necessity for board approval on certain processes that involve data exchange between states."
      ],
      "summary": "This bill amends the procedures and regulations within the prescription monitoring program (PMP) in Minnesota under section 152.126.",
      "modified": [
        "Expands the definition and list of substances that need tracking within the system.",
        "Changes the data retention periods and conditions under which data must be destroyed."
      ]
    },
    "citation": "152.126"
  },
  {
    "analysis": {
      "added": [
        "Aligns terminology to reflect current practices in dispensing medications."
      ],
      "removed": [],
      "summary": "Updates the definition related to dispensing and prescribers under section 151.01.",
      "modified": [
        "Clarifies what constitutes dispensing in the context of PMP reporting."
      ]
    },
    "citation": "151.01"
  },
  {
    "analysis": {
      "added": [],
      "removed": [],
      "summary": "Incorporates changes to the classification and management of controlled substances as prescribed by section 152.02.",
      "modified": [
        "Updates the list of reportable drugs that need monitoring, including opioid antagonists."
      ]
    },
    "citation": "152.02"
  },
  {
    "analysis": {
      "added": [],
      "removed": [],
      "summary": "Includes health licensing board's involvement related to the PMP in section 214.01.",
      "modified": [
        "Sets limits on data access by health licensing boards unless part of an official investigation."
      ]
    },
    "citation": "213.01"
  }
]

Sponsors